Europe Immunohematology Market size was valued at USD 389.2 million in 2017 and is expected to witness 1.9% CAGR from 2018 to 2024.
Europe Immunohematology Market, 2017 & 2024 (USD Million)
Get more details on this report - Request Free Sample PDF
Rising number of road accidents will escalate the demand for blood transfusions thereby, fostering the industry growth. Injury and trauma cases may cause tremendous blood loss resulting in immediate need of blood transfusion. Furthermore, now-a-days, trauma centres as well as blood banks are equipped with advanced medical devices for carrying out blood transfusions efficiently that will boost immunohematology industry growth in coming years.
Increasing number of blood donation awareness program will render positive impact on the immunohematology industry growth. Programs organized by WHO such as ‘Blood and Transfusion Safety’ to support national blood systems that determine timely access to safe and enough supply of blood and blood products will favour business growth. However, stringent regulatory landscape may restrain the industry growth to some extent.
Analysers segment accounted for more than USD 133 million in 2017 and is projected to show robust CAGR during the forthcoming years. Increasing segment growth is attributable to rising demand for high-throughput automatic analyser systems. Moreover, increasing focus of industry players on developing innovative automated immunohematology analysers and systems will favour industry growth. For instance, Cardinal Health and Ortho Clinical Diagnostics has launched ORTHO VISION blood bank analyser with responsive automation technology. Aforementioned factors will boost the segmental growth.
Biochips segment accounted for over 11% revenue share in 2017 owing to several benefits associated with it. They enable researcher to quickly screen large numbers of biological analytes for disease diagnosis. Biochips are being used in toxicological, protein, and biochemical research for rapid detection of chemical agents. Increasing use of biochips for rapid disease diagnosis will increase its adoption rate thereby stimulating segmental growth.
Gel-card segment is forecasted to witness around 2% growth over the forecast timeframe. The gel card systems are widely used for alloantibody identification, antigen detection and cross matching. The technique is safer, quicker and user-friendly. Additionally, it reduces interpretive errors and does not require skilled professionals. Gel card is a first line test, requiring confirmation with monospecific antisera especially for the diagnosis of immune haemolytic anaemias. It is applicable to a wide range of tests routinely performed in the blood bank. It is also used in antibody screening, antigen typing, and crossmatching. Increasing adoption of such technologically advanced blood serology techniques will surge the adoption of gel cards in the foreseeable future.
Diagnostic laboratory segment is expected to witness 2% CAGR over the analysis period. Increasing prevalence of several chronic haematological disorders will propel diagnostics laboratories segment growth. Patients suffering from various disorders need to undergo different diagnostic tests for acute and early diagnosis. Furthermore, diagnostic laboratories are well equipped with advanced diagnostic instruments and technologies. Increasing patient preference towards advanced laboratory diagnostic techniques will boost segmental growth during forthcoming years.
Some of the key industry players include Abbott, ANTISEL S.A., Beckman Coulter, Becton Dickinson, Bio-Rad Laboratories, Diagast, Grifols, Hologic, Immucor, Roche Diagnostics, Siemens Healthcare and ThermoFisher Scientific. These players implement several strategic initiatives such as mergers, acquisitions and new product launches to maintain their market position. Increasing product approvals will also enhance revenue growth. For instance, in January 2018, Bio-Rad received FDA clearance for its IH-Centrifuge L and IH-Incubator L instruments for use with Bio-Rad’s IH-system gel reagents. The product launch expanded company’s existing product portfolio.
Immunohematology industry can be traced back to 20th century. In early 20th century, principles of immunohematology were introduced. In the early phases, PCR technology was utilized in identifying blood disorders. Later as the technology advanced, immunohematology analysers were utilized for determining blood groups. In Europe, immunohematology market is matured due to immense technological advancements. Companies having strong foothold in European countries have adopted technologies enabling modifications in the immunohematology analysers that positively impacts the industry growth. Also, Europe witness’s favourable regulatory scenario for immunohematology industry that should escalate industry growth in coming years.